Molecular Imaging of Glucose Metabolism for Intraoperative Fluorescence Guidance During Glioma Surgery

Mol Imaging Biol. 2021 Aug;23(4):586-596. doi: 10.1007/s11307-021-01579-z. Epub 2021 Feb 5.

Abstract

Purpose: This study evaluated the use of molecular imaging of fluorescent glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) as a discriminatory marker for intraoperative tumor border identification in a murine glioma model.

Procedures: 2-NBDG was assessed in GL261 and U251 orthotopic tumor-bearing mice. Intraoperative fluorescence of topical and intravenous 2-NBDG in normal and tumor regions was assessed with an operating microscope, handheld confocal laser scanning endomicroscope (CLE), and benchtop confocal laser scanning microscope (LSM). Additionally, 2-NBDG fluorescence in tumors was compared with 5-aminolevulinic acid-induced protoporphyrin IX fluorescence.

Results: Intravenously administered 2-NBDG was detectable in brain tumor and absent in contralateral normal brain parenchyma on wide-field operating microscope imaging. Intraoperative and benchtop CLE showed preferential 2-NBDG accumulation in the cytoplasm of glioma cells (mean [SD] tumor-to-background ratio of 2.76 [0.43]). Topically administered 2-NBDG did not create sufficient tumor-background contrast for wide-field operating microscope imaging or under benchtop LSM (mean [SD] tumor-to-background ratio 1.42 [0.72]). However, topical 2-NBDG did create sufficient contrast to evaluate cellular tissue architecture and differentiate tumor cells from normal brain parenchyma. Protoporphyrin IX imaging resulted in a more specific delineation of gross tumor margins than intravenous or topical 2-NBDG and a significantly higher tumor-to-normal-brain fluorescence intensity ratio.

Conclusion: After intravenous administration, 2-NBDG selectively accumulated in the experimental brain tumors and provided bright contrast under wide-field fluorescence imaging with a clinical-grade operating microscope. Topical 2-NBDG was able to create a sufficient contrast to differentiate tumor from normal brain cells on the basis of visualization of cellular architecture with CLE. 5-Aminolevulinic acid demonstrated superior specificity in outlining tumor margins and significantly higher tumor background contrast. Given the nontoxicity of 2-NBDG, its use as a topical molecular marker for noninvasive in vivo intraoperative microscopy is encouraging and warrants further clinical evaluation.

Keywords: 2-NBDG; 5-aminolevulinc acid; Confocal laser endomicroscopy; Fluorescence-guided surgery; Glioma; Protoporphyrin IX.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Chloro-7-nitrobenzofurazan / analogs & derivatives
  • 4-Chloro-7-nitrobenzofurazan / metabolism
  • Aminolevulinic Acid / metabolism
  • Animals
  • Apoptosis / physiology
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Brain / pathology
  • Brain Neoplasms / diagnostic imaging*
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / pathology
  • Brain Neoplasms / surgery
  • Cell Proliferation / physiology
  • Deoxyglucose / analogs & derivatives
  • Deoxyglucose / metabolism
  • Female
  • Fluorescence
  • Glioma / diagnostic imaging*
  • Glioma / metabolism
  • Glioma / pathology
  • Glioma / surgery
  • Glucose / metabolism*
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Molecular Imaging / methods*
  • Monitoring, Intraoperative / methods
  • Protoporphyrins / metabolism
  • Surgery, Computer-Assisted / methods*
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Substances

  • Protoporphyrins
  • Aminolevulinic Acid
  • Deoxyglucose
  • protoporphyrin IX
  • 4-Chloro-7-nitrobenzofurazan
  • Glucose
  • 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose